122 related articles for article (PubMed ID: 1281831)
1. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.
Ortel TL; Quinn-Allen MA; Charles LA; Devore-Carter D; Kane WH
J Clin Invest; 1992 Dec; 90(6):2340-7. PubMed ID: 1281831
[TBL] [Abstract][Full Text] [Related]
2. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain.
Ortel TL; Devore-Carter D; Quinn-Allen M; Kane WH
J Biol Chem; 1992 Feb; 267(6):4189-98. PubMed ID: 1740460
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylserine binding site of the factor Va C2 domain accounts for membrane binding but does not contribute to the assembly or activity of a human factor Xa-factor Va complex.
Majumder R; Quinn-Allen MA; Kane WH; Lentz BR
Biochemistry; 2005 Jan; 44(2):711-8. PubMed ID: 15641797
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
Camire RM; Kalafatis M; Tracy PB
Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
[TBL] [Abstract][Full Text] [Related]
5. A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex.
Majumder R; Quinn-Allen MA; Kane WH; Lentz BR
Blood; 2008 Oct; 112(7):2795-802. PubMed ID: 18587009
[TBL] [Abstract][Full Text] [Related]
6. Bothrojaracin, a proexosite I ligand, inhibits factor Va-accelerated prothrombin activation.
Monteiro RQ; Zingali RB
Thromb Haemost; 2002 Feb; 87(2):288-93. PubMed ID: 11858489
[TBL] [Abstract][Full Text] [Related]
7. Identification of the MMRN1 binding region within the C2 domain of human factor V.
Jeimy SB; Woram RA; Fuller N; Quinn-Allen MA; Nicolaes GA; Dahlbäck B; Kane WH; Hayward CP
J Biol Chem; 2004 Dec; 279(49):51466-71. PubMed ID: 15452129
[TBL] [Abstract][Full Text] [Related]
8. Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V.
Samis JA; Garrett M; Manuel RP; Nesheim ME; Giles AR
Blood; 1997 Aug; 90(3):1065-74. PubMed ID: 9242537
[TBL] [Abstract][Full Text] [Related]
9. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.
Ortel TL; Quinn-Allen MA; Keller FG; Peterson JA; Larocca D; Kane WH
J Biol Chem; 1994 Jun; 269(22):15898-905. PubMed ID: 7515064
[TBL] [Abstract][Full Text] [Related]
10. Isolation and study of an acquired inhibitor of human coagulation factor V.
Nesheim ME; Nichols WL; Cole TL; Houston JG; Schenk RB; Mann KG; Bowie EJ
J Clin Invest; 1986 Feb; 77(2):405-15. PubMed ID: 3944265
[TBL] [Abstract][Full Text] [Related]
11. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.
Ortel TL; Moore KD; Quinn-Allen MA; Okamura T; Sinclair AJ; Lazarchick J; Govindan R; Carmagnol F; Kane WH
Blood; 1998 Jun; 91(11):4188-96. PubMed ID: 9596666
[TBL] [Abstract][Full Text] [Related]
13. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding.
Izumi T; Kim SW; Greist A; Macedo-Ribeiro S; Fuentes-Prior P; Bode W; Kane WH; Ortel TL
Thromb Haemost; 2001 Jun; 85(6):1048-54. PubMed ID: 11434683
[TBL] [Abstract][Full Text] [Related]
14. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.
Lewis DA; Moore KD; Ortel TL
Blood Coagul Fibrinolysis; 2003 Jun; 14(4):361-8. PubMed ID: 12945878
[TBL] [Abstract][Full Text] [Related]
15. Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways.
Hoekema L; Nicolaes GA; Hemker HC; Tans G; Rosing J
Biochemistry; 1997 Mar; 36(11):3331-5. PubMed ID: 9116011
[TBL] [Abstract][Full Text] [Related]
16. Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation.
Jeimy SB; Fuller N; Tasneem S; Segers K; Stafford AR; Weitz JI; Camire RM; Nicolaes GA; Hayward CP
Thromb Haemost; 2008 Dec; 100(6):1058-67. PubMed ID: 19132231
[TBL] [Abstract][Full Text] [Related]
17. Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex.
Nicolaes GA; Villoutreix BO; Dahlbäck B
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):89-100. PubMed ID: 10691103
[TBL] [Abstract][Full Text] [Related]
18. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.
Kim SW; Ortel TL; Quinn-Allen MA; Yoo L; Worfolk L; Zhai X; Lentz BR; Kane WH
Biochemistry; 1999 Aug; 38(35):11448-54. PubMed ID: 10471296
[TBL] [Abstract][Full Text] [Related]
19. Factor V.
Rosing J; Tans G
Int J Biochem Cell Biol; 1997 Oct; 29(10):1123-6. PubMed ID: 9438374
[TBL] [Abstract][Full Text] [Related]
20. The effect of membrane composition on the hemostatic balance.
Smirnov MD; Ford DA; Esmon CT; Esmon NL
Biochemistry; 1999 Mar; 38(12):3591-8. PubMed ID: 10090745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
